PDCD1 and non-small cell lung carcinoma: The multiple therapeutic antibodies that block immune checkpoints, such as cytotoxic programmed cell death protein 1 (PD1, PDCD1) and T lymphocyte associated antigen 4 (CTLA4), showed great effects in treating non-small-cell lung cancer, kidney cancer, and melanoma [5].